Premanand Maharaj is facing a serious kidney problem, admitting both his kidneys have failed and he is undergoing dialysis.
MedPage Today on MSN
Pick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad Say
The European Association for the Study of Obesity recommends the GLP-1 injectables semaglutide and tirzepatide as first-line ...
Indeed, simple liver cysts are almost always asymptomatic and found incidentally during routine testing for something else. These masses are not cancerous and not even dangerous. Simple cysts of the ...
PCOS Awareness Month highlights common questions and misconceptions about Polycystic Ovary Syndrome, offering clarity and ...
Polycystic ovary syndrome (PCOS) is a common hormonal condition which affects the way the ovaries work. According to the NHS, ...
Everyday Health on MSN
Can GLP-1 Drugs for Obesity and Diabetes Also Treat Other Diseases?
Researchers are exploring drugs like Ozempic, Mounjaro, and Wegovy to treat or prevent a range of conditions, including ...
The gastrointestinal neuroendocrine tumors market is experiencing steady growth driven by increasing disease prevalence, improved diagnostic capabilities, ...
14don MSN
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity ...
Del Webb's Karyn and Jerry Waxman are hosting the PKD Applied Underwriters Invitational on Oct. 27 at Lakewood National Golf ...
Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity ...
The European Association for the Study of Obesity (EASO) has called for GLP-1 agonists from Novo Nordisk and Eli Lilly to be ...
Brooke Sears fought for more than two years to get a PCOS diagnosis after doctors told her she just needed to lose weight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results